Perspective
Volume 11:06, 2024

International Journal of Neurorehabilitation

ISSN: 2376-0281 Open Access

Emerging Immunomodulatory Drugs in the Management of Chronic Inflammatory Diseases

Jara Rinkelstin*

Department of Behavioral Neurology, University of Massachusetts, Boston, USA

Introduction

Medications and medical interventions are essential in managing various health conditions, but it's crucial to be aware of their potential side effects, particularly neurological ones, which can significantly affect a patient's quality of life. This review and meta-analysis aim to provide an overview of the neurological side effects linked to different medications and treatments, summarizing existing evidence to highlight their prevalence, severity, and implications for patient care. Psychotropic medications, such as antidepressants, antipsychotics, and mood stabilizers, are frequently associated with neurological side effects. These may include extrapyramidal symptoms, cognitive impairment, sedation, and movement disorders. Understanding these potential effects is key in selecting the right medication and managing any adverse outcomes. Similarly, Antiepileptic Drugs (AEDs), commonly used to treat epilepsy and other neurological conditions, are effective in controlling seizures but may lead to cognitive decline, sedation, dizziness, ataxia, and psychiatric disturbances. To minimize these side effects and achieve the best therapeutic results, careful monitoring and dose adjustments are essential.

Description

Immunosuppressive medications, including corticosteroids and immunomodulatory drugs used to treat autoimmune and inflammatory disorders, can lead to a variety of neurological side effects. These may include mood swings, cognitive dysfunction, peripheral neuropathy, myopathy, and an increased susceptibility to infections. Close monitoring is necessary when using these drugs to carefully weigh the risks and benefits. Chemotherapy agents used in cancer treatment are also commonly associated with neurological side effects. These can include peripheral neuropathy, cognitive impairments, stroke, seizures, and neurotoxicity. Effectively managing these side effects is crucial for optimizing treatment results and preserving the patient's quality of life. Surgical procedures, particularly brain surgery, can also come with neurological risks. These complications may include postoperative cognitive dysfunction, seizures, stroke, and infection. Spinal surgeries, on the other hand, may result in nerve damage, spinal cord injury, or chronic pain. Additionally, certain medications are known to cause motor and movement disorders, ranging from mild tremors to more severe extrapyramidal symptoms [1].

This meta-analysis will also evaluate the quality of the included studies, considering factors such as study design, sample size, and the statistical methods used. By combining data from multiple studies, the analysis can provide a more precise estimate of the overall risk of neurological side effects and identify potential variations across different treatments or patient populations. Neurological side effects linked to medications and medical interventions can significantly affect patient care and treatment outcomes. Therefore, understanding these side effects is essential for healthcare professionals to make well-informed decisions, effectively monitor patients, and minimize risks. This comprehensive review and meta-analysis highlight the importance of recognizing and managing these adverse effects, enabling healthcare providers to deliver safe, effective care. While medications are key in treating various health conditions, they may also carry potential side effects. Among these, neurological side effects are especially concerning due to their possible impact on cognitive function, motor skills, and overall quality of life. This in-depth review and meta-analysis aim to examine the prevalence, characteristics, and clinical significance of neurological side effects associated with commonly prescribed medications [2].

Conclusion

A meta-analysis of studies examining neurological side effects offers valuable insights into their prevalence and associated risk factors. By combining data from multiple studies, a meta-analysis provides a more reliable assessment of the overall occurrence and severity of these side effects. It also helps identify subgroups at higher risk. This approach can contribute to evidence-based decision-making, guide clinical practices, and inform medication choices, especially when neurological side effects may significantly affect patient outcomes. Neurological side effects from commonly prescribed medications can greatly impact patients' well-being and treatment effectiveness. This comprehensive review and meta-analysis provide an in-depth analysis of the prevalence, characteristics, and clinical consequences of these side effects. Understanding the scope and severity of these issues enables healthcare providers to make informed decisions about medication selection, implement timely interventions, and reduce the impact on patients' cognitive function, motor skills, sensory perception, and mental health. Ongoing research and awareness are essential for deepening our understanding of these side effects and enhancing patient safety in medication management.

References

1. Wang, Meiyan, Pei-Chi Wei, Christina K. Lim and Iryna S. Gallina, et al. "Increased neural progenitor proliferation in a hiPSC model of autism induces replication stress-associated genome instability." *Cell Stem Cell* 26 (2020): 221-233.

2. Duarte, Sofia Temudo, Judith Armstrong, Ana Roche and Carlos Ortez, et al. "Abnormal expression of cerebrospinal fluid cation chloride cotransporters in patients with Rett syndrome." *PloS one* 8 (2013): e68851.

***Address for Correspondence:** Jara Rinkelstin, Department of Behavioral Neurology, University of Massachusetts, Boston, USA, E-mail: jararinkelstin5@gmail.com*

Received: 02 December, 2024, Manuscript No. ijn-25-160168; **Editor assigned:** 04 December, 2024, PreQC No. P-160168; **Reviewed:** 14 December, 2024, QC No. Q-160168; **Revised:** 19 December, 2024, Manuscript No. R-160168; **Published:** 26 December, 2024, DOI: 10.37421/2376-0281.2024.11.605

How to cite this article: Rinkelstin, Jara. "Emerging Immunomodulatory Drugs in the Management of Chronic Inflammatory Diseases." *Int J Neurorehabilitation Eng* 11 (2024): 605.